A $10 billion (£7 billion) takeover bid by Australian pharmaceutical giant Sigma Healthcare for UK retail pharmacy chain Boots has collapsed, plunging the company into fresh uncertainty. The deal's demise leaves 51,000 employees and 1,800 stores across the UK in limbo, with Boots' future hanging precariously in the balance.
The news sent Sigma's shares soaring by 6%, a signal of investor relief, according to analysts at Global X ETFs. Marc Jocum, senior product and investment strategist, noted that shareholders appear to favour the company focusing on its established growth strategy, primarily targeting the Australian market, rather than pursuing a large-scale transformational deal.
Boots' protracted sale saga has seen multiple changes in ownership over the past two decades, including mergers with Alliance Unichem and KKR, and a full acquisition by Walgreens in 2014. The recent interest from Sigma had sparked speculation that Boots might rejoin the London Stock Exchange, following reports of its appointment of Alex Baldcock as new chief executive.
Despite this uncertainty, Boots recently reported robust financial performance for the year ending August 2025, with overall revenues increasing by 3.2% to £7.5 billion and pre-tax profit rising by 25% to £337 million. The company's positive financial health may make it an attractive prospect for other potential buyers.
The collapse of talks also raises questions about the broader implications for Boots' workforce, particularly its 6,000 staff at its Beeston headquarters. Canadian investors, including the Weston family, owners of Loblaws and Shoppers Drug Mart, have previously expressed interest in acquiring the company.